FONT-SIZE Plus   Neg

BioSante Pharma Reveals Positive Results Of Its Prostate Cancer Vaccine Study

Specialty pharmaceutical company BioSante Pharmaceuticals Inc (BPAX) Monday announced that the latest issue of The Lancet Oncology published the results from a Phase I dose escalation clinical study of GVAX Prostate cancer vaccine.

The results revealed that the GVAX Prostate cancer vaccine, used in treating metastatic castration-resistant prostate cancer patients in combination with ipilimumab, resulted in 53 percent of patients achieving at least stable disease, with two patients showing clear regression of metastases.

The results further revealed that 23 percent of patients in the higher dose cohorts had confirmed partial PSA response of greater than 50 percent from baseline.

The study further concluded that there were no serious adverse events in the lower dose Ipi cohorts and administration of immunotherapy was well tolerated and safe.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Pilot of an American Airline died as he was flying the Airbus A320 from Phoenix to Boston. The co-pilot managed the situation and made an emergency landing at Syracuse Hancock International airport on Monday. The Flight was carrying 147 passengers and five crew members. Popular social media company Twitter Inc. Monday confirmed that co-founder and one of the largest shareholders Jack Dorsey will be permanent chief executive officer. Xbox Live users are aggravated about repeated outages that have prevented gamers from accessing online multiplayer features.
comments powered by Disqus
Follow RTT